AMAG Pharmaceuticals, Inc. (AMAG) Rating Lowered to Market Perform at Leerink Swann

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) was downgraded by equities research analysts at Leerink Swann to a “market perform” rating in a research note issued on Tuesday.

Other equities research analysts have also issued reports about the company. Needham & Company LLC started coverage on AMAG Pharmaceuticals in a research report on Wednesday, October 26th. They set a “buy” rating and a $40.00 target price on the stock. Janney Montgomery Scott started coverage on AMAG Pharmaceuticals in a research report on Tuesday, January 3rd. They set a “buy” rating and a $45.00 target price on the stock. Guggenheim started coverage on AMAG Pharmaceuticals in a research report on Monday, November 7th. They set a “buy” rating and a $42.00 target price on the stock. J P Morgan Chase & Co reaffirmed a “hold” rating and set a $33.00 target price on shares of AMAG Pharmaceuticals in a research report on Friday, November 4th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $33.00 target price on shares of AMAG Pharmaceuticals in a research report on Wednesday, December 21st. Two analysts have rated the stock with a sell rating, six have given a hold rating and six have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $36.00.

Analyst Recommendations for AMAG Pharmaceuticals (NASDAQ:AMAG)

AMAG Pharmaceuticals (NASDAQ:AMAG) opened at 23.00 on Tuesday. The stock has a 50 day moving average price of $34.15 and a 200-day moving average price of $27.42. AMAG Pharmaceuticals has a 12-month low of $17.92 and a 12-month high of $36.83. The stock has a market capitalization of $786.81 million, a P/E ratio of 52.87 and a beta of 1.01.

AMAG Pharmaceuticals (NASDAQ:AMAG) last announced its earnings results on Thursday, November 3rd. The specialty pharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.50 by $0.28. The company had revenue of $143.80 million for the quarter, compared to analyst estimates of $141.65 million. AMAG Pharmaceuticals had a return on equity of 11.10% and a net margin of 3.12%. AMAG Pharmaceuticals’s revenue for the quarter was up 49.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.02 earnings per share. Equities research analysts expect that AMAG Pharmaceuticals will post $6.02 EPS for the current year.

TRADEMARK VIOLATION WARNING: This story was first posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this story on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The correct version of this story can be read at https://www.com-unik.info/2017/01/10/amag-pharmaceuticals-inc-amag-rating-lowered-to-market-perform-at-leerink-swann.html.

In other AMAG Pharmaceuticals news, SVP Julie Krop sold 4,938 shares of the business’s stock in a transaction dated Thursday, October 20th. The stock was sold at an average price of $24.80, for a total value of $122,462.40. Following the transaction, the senior vice president now owns 23,668 shares in the company, valued at $586,966.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 2.30% of the stock is owned by company insiders.

Several hedge funds have recently made changes to their positions in AMAG. Arizona State Retirement System boosted its stake in shares of AMAG Pharmaceuticals by 0.6% in the second quarter. Arizona State Retirement System now owns 18,000 shares of the specialty pharmaceutical company’s stock worth $431,000 after buying an additional 100 shares in the last quarter. Rothschild Asset Management Inc. boosted its stake in shares of AMAG Pharmaceuticals by 2.6% in the third quarter. Rothschild Asset Management Inc. now owns 9,686 shares of the specialty pharmaceutical company’s stock worth $237,000 after buying an additional 244 shares in the last quarter. BlackRock Inc. boosted its position in AMAG Pharmaceuticals by 6.2% in the third quarter. BlackRock Inc. now owns 7,428 shares of the specialty pharmaceutical company’s stock valued at $182,000 after buying an additional 432 shares in the last quarter. Capstone Asset Management Co. boosted its position in AMAG Pharmaceuticals by 5.1% in the second quarter. Capstone Asset Management Co. now owns 10,876 shares of the specialty pharmaceutical company’s stock valued at $260,000 after buying an additional 530 shares in the last quarter. Finally, Teacher Retirement System of Texas boosted its position in AMAG Pharmaceuticals by 13.8% in the second quarter. Teacher Retirement System of Texas now owns 4,864 shares of the specialty pharmaceutical company’s stock valued at $116,000 after buying an additional 589 shares in the last quarter.

About AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

5 Day Chart for NASDAQ:AMAG

What are top analysts saying about AMAG Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AMAG Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit